. A NONATOPIC woman, 54 years old, was referred for unstable angina. Coronary angiography revealed critical stenosis for which stenting was indicated, and which was performed under i.v. heparin and abciximab, infused for 12 h. Nine days later the patient underwent a generalized exanthemawith a cervicofacial swelling that persisted for several days. A fall in platelet count to 64310/l was observed, in parallel with a rise of eosinophilia from 123/mmto1000/mm.The test forheparin antibodies was negative. The anomalies subsided during the following days and the patientwasdischarged. Since that time two coronary angiographies have been carried out without any incident. Skin tests were carried out nine months and 11 months later. Prick tests, intradermal tests (IDT) and epicutaneous tests were performed and read at 20 min, 24 h, 48 h, 72 h for iodinated contrast media, heparins, danaparoid and low molecular weight (LMW) heparins, betablockers, perindopril andReopro, tested at 0.2 and 2 mg/ml. At 48 h, only the IDT to Reopro were positive to both concentrations. The histology showed a dense perivascular inflammatory infiltrate, mainly composed of lymphocytes.Thewholepopulationwas CD45Ro. Seventy percent of the cells wereCD45Ra, 60%wereCD8, 40%were CD4. Numerous cells in the epidermis were CD1a with some identical cells sheathing the vessels. There were no deposits of immunoglobulins or of complement. Abciximab is a platelet glycoprotein IIb/ IIIa inhibitor. It is the fragment antigen binding portion of a chimeric human–murinemonoclonalantibody.The binding to platelets is irreversible, lasting A case with skin